Clinical trials: Rejection
Kidney Transplant Rejection
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
The purpose of this study is to evaluate the safety of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft…
- Trial name
- CarBel (NCT06918990)
- Testing
- Carfilzomib, Belatacept
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lung Transplant Rejection
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous immunoglobulins for AMR after lung transplantation…
- Trial name
- NCT02474927
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- John F. McDyer, MD
Kidney Transplant Failure and Rejection
Using the Speckle Doppler to Quantify Blood Flow in Kidney and Pancreas Grafts
Kidney and Pancreas transplantation is considered the treatment of choice for many people with End Stage Renal Disease and Type 1 diabetes because quality of life and survival is often better after transplantation.
- Trial name
- NCT04202237
- Testing
- Speckle Doppler imaging, Blood sample
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Manchester University NHS Foundation Trust
Kidney Diseases, Graft Rejection
Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
The main aim of this study is to compare the renal function (serum creatinine at 6 months) in the later introduction of tacrolimus or rapamycin based in immunosuppressor regimes with daclizumab, mycophenolate mofetil, and…
- Trial name
- NCT00290069
- Testing
- Tacrolimus, Rapamycin
- Where
- 7 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Sociedad Andaluza de Trasplantes de Organos y Tejidos
Graft Failure
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Major Objectives A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients who have rejected (<5% T Cell Chimerism) a previous allogeneic hematopoietic stem cell graft by using an…
- Trial name
- NCT00472329
- Testing
- Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN)
Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients
Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term.
- Conditions
- Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
- Trial name
- Mini-Kidney (NCT01531257)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Autoimmune Diseases, Inflammation
Prospective Study of White Blood Cells
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Conditions
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- Trial name
- NCT04838171
- Testing
- White blood cell and blood collection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quell Therapeutics Limited
Graft Rejection, Kidney Transplantation
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better…
- Conditions
- Graft Rejection, Kidney Transplantation, Renal Transplantation
- Trial name
- NCT00035555
- Testing
- Belatacept, Cyclosporine, Mycophenolate mofetil (MMF)
- Where
- 12 sites in United States
- Volunteers
- 230 people
- Sponsor
- Bristol-Myers Squibb
Kidney Transplantation
Predictors and Intervention for Noncompliance
This is a randomized controlled intervention trial in poorly compliant patients, testing whether improved compliance behavior decreases rates of acute rejection risk and graft loss.
- Trial name
- NCT00148174
- Testing
- Intensive telephone followup
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- University of Minnesota
Hypogammaglobulinemia
Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients
This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
- Trial name
- NCT00137748
- Testing
- CMV-Ig
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic
Renal Transplant Recipients
Research Study of ATG and Rituximab in Renal Transplantation
The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
- Trial name
- RESTARRT (NCT01318915)
- Testing
- ATG, Rituximab, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
End-stage Renal Failure, Kidney Graft Rejection
Reference Group Trial for The ONE Study
To investigate the progression of the immunological response in living-donor kidney transplant recipients treated with a standard immunosuppressive regimen.
- Trial name
- NCT01656135
- Testing
- Blood drawing for immune monitoring and questionnaires
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- University of Regensburg
End-stage Renal Disease (ESRD), Kidney Transplantation
Microbiota Changes Related to Outcomes in Kidney Transplantation
Chronic kidney disease affects approximately 10% of the world population. End-stage renal disease (ESRD) is associated with immune dysregulation, chronic inflammation, and alteration of the gut and urinary microbiota.
- Trial name
- MICRO-KT (NCT07893691)
- Testing
- Fecal samples, Urinary sample, Blood samples
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Kidney Transplant Rejection
PROACT Pilot Trial
Kidney transplantation is considered the best option to treat end-stage kidney disease, but the recipient's immune system may respond with rejection to the transplanted organ, leading to permanent kidney damage and failure.
- Trial name
- NCT06564649
- Testing
- CXCL10 Monitoring at clinical frequency
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Rejection, Lung Transplantation
Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation
In patients with acute rejection after lung transplantation the peptide profile in broncho-alveolar lavage (BAL) and urine should be compared in order to identify a paradigm that allows an non-invasive rejection therapy.
- Trial name
- NCT00558597
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Hannover Medical School
Kidney Transplantation
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
The 12 Month Core Study (CRAD001A1202) was designed to evaluate the efficacy and safety comparing concentration-controlled everolimus (1.5 mg/day starting dose) with reduced dose cyclosporine and corticosteroids versus 2 g/day…
- Trial name
- NCT00658320
- Testing
- Everolimus, Mycophenolate mofetil (MMF), Basiliximab
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Novartis
Heart Transplant Failure and Rejection
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
Abnormal lipid metabolism is a common complication after organ transplantation, with pathological changes in lipid parameters occurring in approximately 60-80% of cardiac transplant recipients receiving triple immunotherapy with…
- Trial name
- NCT05994274
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Kidney Transplant Rejection
The TOGETHER Project - Kidney RNA-seq Validation
The researchers are trying to develop a way to measure the risk of rejection through the validation of a blood test.
- Trial name
- TOGETHER (NCT03874299)
- Where
- 3 sites in United States
- Volunteers
- 302 people
- Sponsor
- Mayo Clinic
Liver Transplant, Hepatocellular Carcinoma Recurrent
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
The prognosis of liver transplanted (LT) patients with recurrence of hepatocellular carcinoma (HCC), especially those with progression after locoregional treatment or advanced HCC, remains poor.
- Conditions
- Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
- Trial name
- IMMUNO-TH (NCT06254248)
- Testing
- Systemic therapy
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
Greater than 50% of lung transplant recipients show signs of chronic lung allograft dysfunction (CLAD) by 5 years post-transplantation.Therapies to prevent or slow CLAD are lacking.
- Trial name
- NCT03473340
- Testing
- Pirfenidone Capsule
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Michigan